Business
MedMira Reports Second Quarter Results FY2025
HALIFAX, NS / ACCESS Newswire / June 30, 2025 / MedMira Inc. (MedMira) (TSXV:MIR), reported to...
About this update from Medmira Inc.
MedMira Reports Second Quarter Results FY2025HALIFAX, NS / ACCESS Newswire / June 30, 2025 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the quarter ended January 31, 2025.Corporate updateIn Q3 FY2025, MedMira launched its recently Health Canada approved Multiplo® Rapid TP/HIV Test (Multiplo® TP/HIV) and its latest generation of its Reveal® Rapid HIV Test in Canada through its partner Trimedic. In addition, the Company continued its regulatory work in Canada on two new products and is in the final stages for its clinical trials for the Reveal® G4 HIV-1/2 rapid test CLIA-waiver. Furthermore, the Company signed additional distribution agreements in the USA and achieved VA and Federal listing.Major milestonesIn January 2025, the Company launched its new Health Canada approved Multiplo® TP/HIV and its latest generation of its Reveal® Rapid HIV Test through its partner Trimedic. This launch and the subsequent sales have generated a clear demand for quality STI rapid tests in Canada. MedMira is currently awaiting the regulatory clearance of its Reveal® TP (Syphilis) Antibody Test from Health Canada and with it offer the only Health Canada approved single syphilis antibody rapid test. At the same time, MedMira is in additional clinical trials to obtain further approvals in Canada to increase its product offering and with it allowing customers to choose which test they need or prefer. The Company aims to substantially increase its sexually transmitted (STD) disease product portfolio in Canada and aims to pursue a market leadership for these products in Canada.In Q3 FY2025, the Company in partnership with REACH Nexus have received the ITA (investigational testing authorization) for self-testing application for its Multiplo® TP/HIV. As a result, clinical trials have started with the anticipated aim to complete in the next three months. This would allow the Company to be the first TP/HIV self test in Canada and reach markets and customers beyond the traditional healthcare setting.During Q3 FY2025, the Company, together with its partners, continued its regulatory efforts on the Multiplo® Complete Syphilis (TP/nTP) Antibody Test (Multiplo® TP/nTP). Subsequent to Q3 FY2025, the first phase of clinical trials was successfully completed in Ottawa, sponsored by the Public Health Agency of...